Understanding the regulatory mechanisms that control Nrf2 protein levels, along with the molecular mechanisms of UPS and autophagy, will guide the future development of Nrf2-targeted therapeutics in AMD [1]. The gene discussed is NFE2L2; the disease is age-related macular degeneration.